Monitoring the impact of malaria vaccine rollout on awareness, perceptions and coverage of seasonal malaria chemoprevention: Insights from routine programmatic data in Burkina Faso

Authors: Benoit Sawadogo, Ebenezer Ikechukwu, Monica A de Cola, Anna Fallon, Samuel Kafando, Clotaire Tapsoba, Sidzabda Kompaore, Christian Rassi, Chukwudi A Nnaji

Introduction of the RTS,S/AS01 malaria vaccine in Burkina Faso did not appear to reduce SMC coverage or caregiver confidence during the 2024 round. Findings indicate both interventions can coexist effectively.

The World Health Organization (WHO) has recommended two malaria vaccines to support malaria control and elimination strategies alongside existing preventive measures. However, the potential impact of the malaria vaccine rollout on the uptake of established interventions such as seasonal malaria chemoprevention (SMC) remains unclear. In 2024, Burkina Faso introduced the RTS,S/AS01 vaccine in selected priority districts.[2] This study examined whether the introduction of the malaria vaccine affected SMC coverage, as well as caregiver awareness and perceptions.

This poster was presented at the 2025 Annual Meeting of the American Society of Tropical Medicine and Hygiene, held on 9-13 November in Toronto, Canada.